Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,500,640
-$21,311,064 QoQ
Shares Held
139,079
-93.5% QoQ
Ownership
0.285%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Vestal Point Capital, LP holds $2,697,459,670 across 67 Biotechnology names. URGN ranks #60 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,375,000 | $230,968,750 | |
| 2 | BMRN |
Biomarin Pharmaceutical Inc
|
3,575,000 | $201,951,750 | |
| 3 | ABVX |
Abivax S.A.
|
1,500,000 | $167,025,000 | |
| 4 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
2,275,000 | $142,642,500 | |
| 5 | ELVN |
Enliven Therapeutics, Inc.
|
3,250,000 | $127,400,000 | |
| 6 | BCAX |
Bicara Therapeutics Inc.
|
5,425,000 | $107,903,250 | |
| 7 | NRIX |
Nurix Therapeutics, Inc.
|
6,500,000 | $100,750,000 | |
| 8 | APGE |
Apogee Therapeutics, Inc.
|
1,100,000 | $92,587,000 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,500,640 | 139,079 | Shares | Sole | 2026-05-15 | |
| 2025-03-31 | $23,811,704 | 2,152,957 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $17,359,500 | 1,630,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $5,080,000 | 400,000 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||